- Home
- REX vs OCS Comparison
REX vs OCS Comparison
Compare REX & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REX
- OCS
- Stock Information
- Founded
- REX 1980
- OCS 2003
- Country
- REX United States
- OCS Switzerland
- Employees
- REX N/A
- OCS N/A
- Industry
- REX Major Chemicals
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- REX Industrials
- OCS Health Care
- Exchange
- REX Nasdaq
- OCS Nasdaq
- Market Cap
- REX 800.0M
- OCS 953.8M
- IPO Year
- REX N/A
- OCS N/A
- Fundamental
- Price
- REX $41.44
- OCS $22.64
- Analyst Decision
- REX Strong Buy
- OCS Strong Buy
- Analyst Count
- REX 1
- OCS 5
- Target Price
- REX $55.00
- OCS $28.80
- AVG Volume (30 Days)
- REX 200.0K
- OCS 104.7K
- Earning Date
- REX 12-03-2024
- OCS 03-17-2025
- Dividend Yield
- REX N/A
- OCS N/A
- EPS Growth
- REX 37.28
- OCS N/A
- EPS
- REX 3.82
- OCS N/A
- Revenue
- REX $671,877,000.00
- OCS $1,027,571.00
- Revenue This Year
- REX N/A
- OCS $6.21
- Revenue Next Year
- REX $8.80
- OCS $760.04
- P/E Ratio
- REX $10.86
- OCS N/A
- Revenue Growth
- REX N/A
- OCS N/A
- 52 Week Low
- REX $39.02
- OCS $10.55
- 52 Week High
- REX $60.79
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- REX 43.22
- OCS 85.17
- Support Level
- REX $41.33
- OCS $21.80
- Resistance Level
- REX $43.12
- OCS $23.08
- Average True Range (ATR)
- REX 1.02
- OCS 0.57
- MACD
- REX -0.03
- OCS 0.43
- Stochastic Oscillator
- REX 11.54
- OCS 92.90
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.